vidofludimus calcium
IMU-838 Small Molecule Target: DHODH, Nurr1
Immunic
Most recent annual filing: 2026-02-26
- vidofludimus calcium readout2026vidofludimus calcium readout, 2026, notable
- vidofludimus calcium PPMS Ph3 start2H 2026vidofludimus calcium PPMS Ph3 start, 2H 2026, routine
- vidofludimus calcium Ph3 toplineBy end of 2026vidofludimus calcium Ph3 topline, By end of 2026, thesis-defining
- vidofludimus calcium RMS NDA filingMid-2027vidofludimus calcium RMS NDA filing, Mid-2027, material
- vidofludimus calcium RMS FDA approval2028vidofludimus calcium RMS FDA approval, 2028, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Technology platforms
Nurr1 platform
Nuclear receptor-related 1 (Nurr1) activation platform comprising next-generation small molecule derivatives (IMU-381 series) targeting neurologic, gastrointestinal, and autoimmune diseases
Targets: Nurr1
Biotech Distilled coverage (2)
- 2026-08-12 UPDATE: Immunic (IMUX) - The Founder Is Gone and the Auditors Priced a Sale at 50/50 🔒 Paid
- 2026-05-28 Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.